Avibactam/aztreonam - AstraZeneca/Allergan

Drug Profile

Avibactam/aztreonam - AstraZeneca/Allergan

Alternative Names: ATM-AVI; Aztreonam-avibactam; PF-06947387

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Biomedical Advanced Research and Development Authority; Innovative Medicines Initiative; Pfizer
  • Class Amides; Antibacterials; Heterocyclic bicyclo compounds; Monobactams; Small molecules; Sulfates
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Gram-negative infections
  • Phase II Intra-abdominal infections

Most Recent Events

  • 11 Jul 2018 Pfizer, in collaboration with Allergan, plans a phase III trial for Gram-negative infections in September 2018 (NCT03580044) (EudraCT2017-004544-38)
  • 05 Apr 2018 Phase-III clinical trials in Gram-negative infections (Combination therapy) in USA (IV) (NCT03329092)
  • 05 Apr 2018 Phase-III clinical trials in Gram-negative infections (Monotherapy) in USA (IV) (NCT03329092)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top